Medication leaflets

Active substance

Results for the substance emicizumab

5 results

About this active substance

Emicizumab is a monoclonal antibody used for the prophylaxis and treatment of hemophilia A, particularly in patients with factor VIII inhibitors. It works by mimicking the activity of factor VIII, facilitating blood clotting.

The medication is administered as a subcutaneous injection, usually once weekly or at longer intervals, as directed by a doctor.

Side effects may include injection site reactions, headaches, fatigue, or nausea. In rare cases, thrombotic events or severe allergic reactions may occur.

Emicizumab is not recommended for patients with hypersensitivity to this medication or any of its components.